Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

Sadiya S Khan; Chiadi E Ndumele; Dhruv S Kazi

doi:10.1001/jama.2024.22284

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

JAMA. 2024 Nov 13. doi: 10.1001/jama.2024.22284. Online ahead of print.

Authors

Sadiya S Khan^{1

2}, Chiadi E Ndumele³, Dhruv S Kazi^{4

5}

Affiliations

¹ Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
³ Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
⁴ Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
⁵ Division of Cardiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.

PMID: 39535741
DOI: 10.1001/jama.2024.22284

No abstract available

Plain language summary

This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.